ABVC BioPharma, Inc. (ABVC) stock
ABVCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ECOC
$0.94+0.00 (0.00%)
Close on Nov 17, 2026Market cap $25.06MP/E –Yield –
ABVC BioPharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ABVC BioPharma's operating income for the twelve months ending Jun 30, 2026 was -$6.52M. For fiscal 2025 it was -$7.15M. The highest annual figure on record is -$177.26K in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.15M | – |
| FY2024 | Dec 31, 2024 | -$4.71M | – |
| FY2023 | Dec 31, 2023 | -$6.77M | – |
| FY2022 | Dec 31, 2022 | -$15.11M | – |
| FY2021 | Dec 31, 2021 | -$11.71M | – |
| FY2020 | Dec 31, 2020 | -$8.51M | – |
| FY2019 | Dec 31, 2019 | -$3.46M | – |
| FY2017 | Sep 30, 2017 | -$4.00M | – |
| FY2016 | Sep 30, 2016 | -$11.00M | – |
| FY2013 | Sep 30, 2013 | -$177.26K | – |
| FY2012 | Sep 30, 2012 | -$1.14M | – |
| FY2011 | Sep 30, 2011 | -$1.89M | – |
| FY2010 | Sep 30, 2010 | -$1.89M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$779.53K | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$1.57M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$2.20M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$1.96M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$2.29M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$693.01K | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$704.56K | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$302.32K | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$860.11K | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$2.84M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$511.84K | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$2.15M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$2.19M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$1.91M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$3.13M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$3.72M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$2.05M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$6.22M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$6.45M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$1.97M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$2.04M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$1.25M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$4.85M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$1.29M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$1.19M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$1.17M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$1.12M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$1.12M | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$488.81K | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$730.57K | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$3.36M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$189.48K | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$236.84K | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$210.39K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$647.78K | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$289.10K | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | -$6.61M | – |
| Q1 FY2016CQ4 2015 | Dec 31, 2015 | -$3.50M | – |
| Q3 FY2015CQ2 2015 | Jun 30, 2015 | -$1.50K | – |
See a number that looks wrong?